Influence of Antidepressants on the Relationship Between Disease Duration and Depressive Symptoms in Multiple Sclerosis

OBJECTIVE: Studies have not shown an association between multiple sclerosis (MS) disease duration and depression among people with MS. However, whether antidepressant use influences this possible relationship remains unknown. The authors evaluated whether antidepressant use moderates the association between disease duration and clinically significant depressive symptoms among individuals with MS. METHODS: A consecutive sample of 1,076 adults with MS received psychometric testing during clinical care at a tertiary neuropsychiatry clinic in Toronto from 2020 to 2025. Demographic and disease-related data were gathered via retrospective chart review. A logistic regression analysis adjusted for age, sex, education, Expanded Disability Status Scale (EDSS) scores, and Symbol Digit Modalities Test scores was undertaken to evaluate whether the interaction between antidepressant use and disease duration predicted clinically significant depression (Hospital Anxiety and Depression Scale depression subscale score ≥8). Stratified by antidepressant use, secondary regression analyses controlling for the same covariates were used to evaluate whether disease duration was independently associated with depression. Statistical significance was set at p<0.05. RESULTS: Mean participant age was 43.9±11.5 years, 76% were women, the mean length of education was 16.0±3.1 years, and the median EDSS score was 2.0 (interquartile range 1.5-3.5). Antidepressant use significantly moderated the relationship between disease duration and clinically significant depressive symptoms (p=0.017). In the absence of antidepressants, increased disease duration predicted elevated odds of depression (OR=1.02, p=0.038) but not in the presence of antidepressants (OR=0.98). CONCLUSIONS: Antidepressant use is associated with a lessened influence of prolonged disease duration on an increased odds of clinically significant depression among people with MS.

Authors

Institutions

Publication Details

Journal
Journal of Neuropsychiatry
Published
2026-09-17
DOI
https://doi.org/10.1176/appi.neuropsych.20260024
Primary Topic
Multiple Sclerosis Research Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

Influence of Antidepressants on the Relationship Between Disease Duration and Depressive Symptoms in Multiple Sclerosis

Anthony Feinstein, Jiwon Oh, David Freedman
Journal of Neuropsychiatry
Multiple Sclerosis Research Studies
article

Influence of Antidepressants on the Relationship Between Disease Duration and Depressive Symptoms in Multiple Sclerosis

Anthony Feinstein, Jiwon Oh, David Freedman
article en

Abstract

OBJECTIVE: Studies have not shown an association between multiple sclerosis (MS) disease duration and depression among people with MS. However, whether antidepressant use influences this possible relationship remains unknown. The authors evaluated whether antidepressant use moderates the association between disease duration and clinically significant depressive symptoms among individuals with MS. METHODS: A consecutive sample of 1,076 adults with MS received psychometric testing during clinical care at a tertiary neuropsychiatry clinic in Toronto from 2020 to 2025. Demographic and disease-related data were gathered via retrospective chart review. A logistic regression analysis adjusted for age, sex, education, Expanded Disability Status Scale (EDSS) scores, and Symbol Digit Modalities Test scores was undertaken to evaluate whether the interaction between antidepressant use and disease duration predicted clinically significant depression (Hospital Anxiety and Depression Scale depression subscale score ≥8). Stratified by antidepressant use, secondary regression analyses controlling for the same covariates were used to evaluate whether disease duration was independently associated with depression. Statistical significance was set at p<0.05. RESULTS: Mean participant age was 43.9±11.5 years, 76% were women, the mean length of education was 16.0±3.1 years, and the median EDSS score was 2.0 (interquartile range 1.5-3.5). Antidepressant use significantly moderated the relationship between disease duration and clinically significant depressive symptoms (p=0.017). In the absence of antidepressants, increased disease duration predicted elevated odds of depression (OR=1.02, p=0.038) but not in the presence of antidepressants (OR=0.98). CONCLUSIONS: Antidepressant use is associated with a lessened influence of prolonged disease duration on an increased odds of clinically significant depression among people with MS.

Journal of Neuropsychiatry
St. Michael's Hospital (CA), Sunnybrook Health Science Centre (CA), University of Toronto (CA), Health Sciences Centre (CA), St Michael’s Hospital (IE), St Michaels Hospital (GB)
Good health and well-being
Openalex Percentile: Top 11%
Multiple Sclerosis Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.